Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
Seres Therapeutics (Nasdaq: MCRB) announced it will host a conference call and live audio webcast on November 13, 2024 at 8:30 a.m. ET to discuss third quarter 2024 financial results and provide business updates. Participants can access the call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID 5051385. A webcast replay will be available on the company's website for approximately 21 days after the event.
Seres Therapeutics (Nasdaq: MCRB) ha annunciato che ospiterà una conference call e un webcast audio dal vivo il 13 novembre 2024 alle 8:30 a.m. ET per discutere i risultati finanziari del terzo trimestre 2024 e fornire aggiornamenti sull'attività. I partecipanti possono accedere alla chiamata componendo il numero 800-715-9871 (nazionale) o 646-307-1963 (internazionale) con l'ID conferenza 5051385. Una registrazione del webcast sarà disponibile sul sito web dell'azienda per circa 21 giorni dopo l'evento.
Seres Therapeutics (Nasdaq: MCRB) anunció que llevará a cabo una llamada de conferencia y una transmisión de audio en vivo el 13 de noviembre de 2024 a las 8:30 a.m. ET para discutir los resultados financieros del tercer trimestre de 2024 y proporcionar actualizaciones sobre el negocio. Los participantes pueden acceder a la llamada marcando el 800-715-9871 (nacional) o el 646-307-1963 (internacional) con el ID de conferencia 5051385. Una repetición de la transmisión estará disponible en el sitio web de la empresa durante aproximadamente 21 días después del evento.
세레스 테라퓨틱스(Nasdaq: MCRB)는 2024년 11월 13일 오전 8시 30분 ET에 2024년 3분기 재무 결과와 비즈니스 업데이트를 논의하기 위해 컨퍼런스 콜 및 실시간 오디오 웨비나를 진행한다고 발표했습니다. 참가자는 800-715-9871(국내) 또는 646-307-1963(국제)로 전화하여 회의 ID 5051385로 접속할 수 있습니다. 웨비나 재생은 이벤트 후 약 21일 동안 회사 웹사이트에서 제공됩니다.
Seres Therapeutics (Nasdaq: MCRB) a annoncé qu'elle organisera une conférence téléphonique et un webcast audio en direct le 13 novembre 2024 à 8h30 ET pour discuter des résultats financiers du troisième trimestre 2024 et fournir des mises à jour sur les activités. Les participants peuvent accéder à l'appel en composant le 800-715-9871 (national) ou le 646-307-1963 (international) avec l'ID de conférence 5051385. Un enregistrement du webcast sera disponible sur le site web de l'entreprise pendant environ 21 jours après l'événement.
Seres Therapeutics (Nasdaq: MCRB) gab bekannt, dass am 13. November 2024 um 8:30 Uhr ET eine Telefonkonferenz und ein Live-Audio-Webcast stattfinden werden, um die Finanzergebnisse des dritten Quartals 2024 zu besprechen und geschäftliche Updates bereitzustellen. Teilnehmer können sich unter der Nummer 800-715-9871 (national) oder 646-307-1963 (international) mit der Konferenz-ID 5051385 in die Sitzung einwählen. Eine Wiederholung des Webcasts wird ungefähr 21 Tage nach der Veranstaltung auf der Website des Unternehmens verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 13, 2024 at 8:30 a.m. ET to discuss third quarter 2024 financial results and provide business updates.
To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 5051385. To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). SER-155 and our other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via single-strain cultivation, rather than from the donor-sourced production process used for VOWST. The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. For more information, please visit www.serestherapeutics.com.
Investor and Media Contact:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
When will Seres Therapeutics (MCRB) report Q3 2024 earnings?
How can I access Seres Therapeutics (MCRB) Q3 2024 earnings call?
How long will Seres Therapeutics (MCRB) Q3 2024 earnings webcast be available?
